YOLFTbeta
Eupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals Inc. Common Stock

EPRX · NASDAQ · Healthcare / Biotechnology

8.15USD+0.34 (+4.35%)

Price History

Full chart

Market Stats

Previous Close7.81
Open7.81
Day Range7.61 – 8.23
52-Week Range5.25 – 9.32
Volume774.44K
Market Cap529.25M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.02
Dividend Yield0.00%
Beta1.49
50-Day Avg7.11
200-Day Avg7.27

About

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. James A. Helliwell FRCPC, M.D.
  • Employees49
  • Headquarters2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4, USA
  • Websitehttps://www.eupraxiapharma.com

Leadership

  • Dr. James A. Helliwell FRCPC, M.D.CEO & Director · b. 1974
  • Mr. Alexander John Rothwell Eng., M.B.A.Chief Financial Officer · b. 1969
  • Mr. Paul Anthony Brennan B.Sc., M.Sc.Chief Corporate Development Officer
  • Ms. Wajida Leclerc B.A., CCP, CHRPExecutive Vice President Corporate Services & People · b. 1960
  • Mr. Alex TherienExecutive VP of R&D
  • Dr. Jeymi Tambiah M.S.Chief Medical Officer
  • Dr. Jeffrey Millard Ph.d.Executive Vice President of Technical Operations · b. 1976

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---000000
Cost of Revenue86.62K125.43K207.44K117.07K112.38K193.27K209.91K163.47K331.89K
Gross Profit-86.62K-125.43K-207.44K-117.07K-112.38K-193.27K-209.91K-163.47K-331.89K
Operating Expense4.84M11.90M6.62M2.36M18.26M17.42M20.76M26.84M38.10M
Operating Income-4.93M-12.02M-6.82M-2.47M-18.38M-17.62M-20.97M-27.00M-38.43M
EBITDA-4.93M-14.52M-5.73M-2.02M-17.85M-17.86M-20.78M-24.97M-38.35M
Net Income-4.38M-13.19M-7.37M-4.01M-23.96M-18.49M-21.25M-25.50M-38.58M
R&D3.36M6.80M3.52M1.09M10.17M13.63M15.33M16.08M21.33M
Interest Expense52.81K142.17K1.46M1.88M1.16M982.86K881.05K603.57K0

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.93M2.91M3.29M1.45M31.22M25.89M15.26M34.94M86.15M
Total Liabilities735.82K14.34M21.42M23.12M12.10M16.13M14.59M3.10M5.70M
Total Equity5.98M-11.06M-17.69M-21.21M19.95M10.54M1.67M33.40M82.04M
Cash4.05M823.48K1.16M150.13K20.89M24.73M14.56M33.10M80.56M
Total Debt12.47K3.79M11.94M12.77M9.99M12.17M7.87M71.86K154.36K
Net Debt-4.04M2.97M10.78M12.62M-10.90M-12.56M-6.69M-33.03M-80.41M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.30M-8.32M-5.17M-403.78K-11.58M-14.40M-15.62M-29.99M-29.03M
Investing Cash Flow-314.69K-141.86K-1.90M24.62K-11.42M9.83M-55.25K-75.16K-598.77K
Financing Cash Flow9.47M5.30M7.40M-626.64K39.46M10.80M15.87M45.78M77.33M
Capital Expenditure314.69K141.86K9.48K0341.28K235.55K55.25K104.23K598.77K
Free Cash Flow-5.61M-8.46M-5.18M-403.78K-11.92M-14.63M-15.68M-30.10M-29.63M
FCF to OCF105.94%101.70%100.18%100.00%102.95%101.64%100.35%100.35%102.06%

Earnings

Report DateAug 16, 2021Nov 11, 2021Mar 29, 2022May 6, 2022Aug 12, 2022Nov 8, 2022Mar 24, 2023May 18, 2023Aug 14, 2023Nov 15, 2023Apr 1, 2024Aug 8, 2024Nov 7, 2024Mar 20, 2025May 6, 2025Aug 12, 2025Nov 4, 2025Mar 12, 2026May 7, 2026Aug 11, 2026Nov 3, 2026
EPS Estimate-----------0.18-0.17-0.13-0.12-0.17-0.18-0.19-0.16-0.17-0.25-0.27
EPS Actual-0.33-0.28-0.21-0.20-0.24-0.17-0.30-0.17-0.26-0.18-0.32-0.17-0.17-0.21-0.21-0.26-0.19-0.37-0.23-0.23-
Surprise-----------77.78%0.82%-30.77%-68.72%-23.53%-44.44%0.00%-131.25%-37.64%8.00%-
Timing----------After-hours-After-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap529.25M
Enterprise Value430.68M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book5.00
EPS-1.02
Book Value1.55
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-56.87M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-66.70%
Return on Assets-43.66%
Shares Outstanding66.07M
Shares Float55.67M
Beta1.49
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
43.16%
Insiders
13.98%
Retail / Other
42.86%

Top Institutional Holders

  • Beutel, Goodman & Company Ltd.
    3.67M5.55%
  • Affinity Asset Advisors, LLC
    1.65M2.50%
  • Balyasny Asset Management LLC
    1.35M2.04%
  • Vivo Capital, LLC
    1.35M2.04%
  • Scotia Capital Inc
    1.34M2.03%
  • Ikarian Capital, LLC
    1.21M1.84%
  • Partner Fund Management LP
    1.21M1.83%
  • Great Point Partners LLC
    1.20M1.82%
  • Point72 Asset Management, L.P.
    967.58K1.46%
  • UBS Group AG
    762.63K1.15%
  • Rubric Capital Management LP
    691.17K1.05%
  • Ameriprise Financial Inc
    649.07K0.98%
  • Redmile Group, LLC
    611.40K0.93%
  • Citadel Advisors Llc
    502.01K0.76%
  • Millennium Management LLC
    441.59K0.67%
  • Woodline Partners LP
    440.55K0.67%
  • Seven Fleet Capital Management LP
    433.51K0.66%

Top Fund Holders

  • Dynamic Small Business
    2.00M3.03%
  • Beutel Goodman Small Cap D
    1.72M2.61%
  • IG Beutel Goodman Canadian Small Cap C
    561.73K0.85%